Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032.
AUTOR(ES)
Dong, M Y
RESUMO
LY146032, an acidic lipopeptide antibiotic which inhibits the biosynthesis of cell wall peptidoglycan, was found to be effective in delaying death in a hamster model of pseudomembranous colitis. A dose of 0.05 mg/day was effective. The equivalent protection with vancomycin required a dose 100-fold higher, i.e., 5 mg/day.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174884Documentos Relacionados
- In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
- Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
- In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.
- In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
- Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.
